Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00099580 | PROCLAIM: Effect of AC2592 Administered by Continuous Subcutaneous Infusion in Subjects With Advanced Chronic Congestive Heart Failure | PHASE2 | COMPLETED | 61 | — | — | Mar 1, 2005 | Sep 1, 2006 | Jan 19, 2015 | 29 | United States |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| AC2592 | DRUG | continuous subcutaneous infusion (via pump), dose based on subject body weight |
| placebo | DRUG | continuous subcutaneous infusion (via pump), dose based on subject body weight |
Main Inclusion Criteria: * Has heart failure classified as New York Heart Association (NYHA) Class III or Class IV at screening despite treatment with standard therapy. * Is able to perform a treadmill test. * Has an HbA1c of \<= 11%. * Is physically and mentally capable of operating the continuous...